menu
    • menu
    [{"orgOrder":0,"company":"Neurotech International","sponsor":"Fenix Innovation Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"NTI164","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurotech International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotech International \/ Neurotech International","highestDevelopmentStatusID":"10","companyTruncated":"Neurotech International \/ Neurotech International"},{"orgOrder":0,"company":"Neurotech International","sponsor":"Fenix Innovation Group","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"NTI164","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Neurotech International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotech International \/ Neurotech International","highestDevelopmentStatusID":"9","companyTruncated":"Neurotech International \/ Neurotech International"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurotech International

    Menu

    Neurotech International

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurotech International

                            Australia arrow
                            Global ChemShow
                            Not Confirmed

                            Neurotech International

                            Australia arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTI164

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Fenix Innovation Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NTI164 in Autism Spectrum Disorder

                            Details : NTI164 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Autistic Disorder.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 02, 2025

                            Lead Product(s) : NTI164

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Fenix Innovation Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurotech International

                            Australia arrow
                            Global ChemShow
                            Not Confirmed

                            Neurotech International

                            Australia arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTI164

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Recipient : Fenix Innovation Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

                            Details : NTI164 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Rett Syndrome.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 02, 2025

                            Lead Product(s) : NTI164

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Fenix Innovation Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth